The Public Health Impact of Coccidioidomycosis in Arizona and California

被引：82
作者：
Hector, Richard F. [1 ]
Rutherford, George W. [1 ]
Tsang, Clarisse A. [2 ]
Erhart, Laura M. [2 ]
McCotter, Orion [2 ]
Anderson, Shoana M. [2 ]
Komatsu, Kenneth [2 ]
Tabnak, Farzaneh [3 ]
Vugia, Duc J. [3 ]
Yang, Ying [3 ]
Galgiani, John N. [4 ]
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94105 USA
[2] Arizona Dept Hlth Serv, Phoenix, AZ 85007 USA
[3] Calif Dept Publ Hlth, Infect Dis Branch, DCDC, CID, Sacramento, CA 95899 USA
[4] Univ Arizona, Coll Med, Valley Fever Ctr Excellence, Tucson, AZ 85724 USA
来源：
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH | 2011年 / 8卷 / 04期
关键词：
coccidioidomycosis; community-acquired pneumonia; diagnostics; azoles; vaccine; LIPOSOMAL AMPHOTERICIN-B; NONMENINGEAL COCCIDIOIDOMYCOSIS; PULMONARY COCCIDIOIDOMYCOSIS; POSACONAZOLE THERAPY; CLINICAL SPECIMENS; SEROLOGIC TESTS; VACCINE; POSADASII; EFFICACY; IMMITIS;
D O I：
10.3390/ijerph8041150
中图分类号：
X [环境科学、安全科学];
学科分类号：
08 ; 0830 ;
摘要：
The numbers of reported cases of coccidioidomycosis in Arizona and California have risen dramatically over the past decade, with a 97.8% and 91.1% increase in incidence rates from 2001 to 2006 in the two states, respectively. Of those cases with reported race/ethnicity information, Black/African Americans in Arizona and Hispanics and African/Americans in California experienced a disproportionately higher frequency of disease compared to other racial/ethnic groups. Lack of early diagnosis continues to be a problem, particularly in suspect community-acquired pneumonia, underscoring the need for more rapid and sensitive tests. Similarly, the inability of currently available therapeutics to reduce the duration and morbidity of this disease underscores the need for improved therapeutics and a preventive vaccine.
引用
收藏
页码：1150 / 1173
页数：24
相关论文
共 91 条
[1]   The complex immunology of human coccidioidomycosis [J].
Ampel, Neil M. .
COCCIDIOIDOMYCOSIS: SIXTH INTERNATIONAL SYMPOSIUM, 2007, 1111 :245-258
[2]   Factors and Outcomes Associated with the Decision to Treat Primary Pulmonary Coccidioidomycosis [J].
Ampel, Neil M. ;
Giblin, Andrea ;
Mourani, John P. ;
Galgiani, John N. .
CLINICAL INFECTIOUS DISEASES, 2009, 48 (02) :172-178
[3]   Combating opportunistic infections: coccidioidomycosis [J].
Ampel, NM .
EXPERT OPINION ON PHARMACOTHERAPY, 2004, 5 (02) :255-261
[4]   Coccidioidomycosis in Arizona: Increase in incidence from 1990 to 1995 [J].
Ampel, NM ;
Mosley, DG ;
England, B ;
Vertz, PD ;
Komatsu, K ;
Hajjeh, RA .
CLINICAL INFECTIOUS DISEASES, 1998, 27 (06) :1528-1530
[5]  
Barnato AE, 2001, EMERG INFECT DIS, V7, P797
[6]  
Bartlett John G., 2000, Clinical Infectious Diseases, V31, P347, DOI 10.1086/313954
[7]   Detection of Coccidioides species in clinical specimens by real-time PCR [J].
Binnicker, M. J. ;
Buckwalter, S. P. ;
Eisberner, J. J. ;
Stewart, R. A. ;
McCullough, A. E. ;
Wohlfiel, S. L. ;
Wengenack, N. L. .
JOURNAL OF CLINICAL MICROBIOLOGY, 2007, 45 (01) :173-178
[8]   Coccidioidomycosis in patients who have undergone transplantation [J].
Blair, Janis E. .
COCCIDIOIDOMYCOSIS: SIXTH INTERNATIONAL SYMPOSIUM, 2007, 1111 :365-376
[9]   Outcomes among Inmates Treated for Coccidioidomycosis at a Correctional Institution during a Community Outbreak, Kern County, California, 2004 [J].
Burwell, Lauren A. ;
Park, Benjamin J. ;
Wannemuehler, Kathleen A. ;
Kendig, Newton ;
Pelton, James ;
Chaput, Emma ;
Jinadu, Babatunde A. ;
Emery, Kirt ;
Chavez, Gil ;
Fridkin, Scott K. .
CLINICAL INFECTIOUS DISEASES, 2009, 49 (11) :E113-E119
[10]   Safety, tolerance, and efficacy of posaconazole therapy in patients with nonmeningeal disseminated or chronic pulmonary coccidioidomycosis [J].
Catanzaro, Antonino ;
Cloud, Gretchen A. ;
Stevens, David A. ;
Levine, Bernard E. ;
Williams, Paul L. ;
Johnson, Royce H. ;
Rendon, Adrian ;
Mirels, Laurence F. ;
Lutz, Jon E. ;
Holloway, Melissa ;
Galgiani, John N. .
CLINICAL INFECTIOUS DISEASES, 2007, 45 (05) :562-568
12345678910